グリチルリチン注射剤「ミノフィット」（プレフィルドシリンジ製剤）の有用性について
スポンサーリンク
概要
- 論文の詳細を見る
We evaluated the usefulness of"Minofit®"glycyrrhizin injection,a prefilled syringe (PFS) product,as regards speed and ease of dispensing,β-glycyrrhizic acid (β-GZ) content,impurities,and clinical effects when administered intravenously.Compared with ampules,the PFS shortened the dispensing time to about 1/2 for 20mL of the drug and to about 2/5 for 40mL of the drug.Upon measuring the contents of β-GZ,α-glycyrrhizic acid (α-GZ),glycyrrhetic acid (GA),and glycyrrhetic acid monoglucuronide (MGGR) by HPLC,we found that the β-GZ content was 1.940mg/mL for Minofit® and 1.833mg/mL for the Stronger neo-minophagen-C® (SNMC) product.The α-GZ form accounted for less than 5% of the β-GZ content and GA and MGGR each accounted for less than 0.15% of the glycyrrhizic acid content.The contents of major impurities were similar for both Minofit® and SNMC.To evaluate the clinical effects in 28 patients with hepatitis C (excluding HCC) who were continuously treated using SNMC for 6 months and using Minofit® for the next 6 months or longer,the ALT and AST values immediately before the change to Minofit® were compared with those 6 months after the change.The mean ALT value was 54.8±25.9 IU/L before the change and 46.8±26.0 IU/L afterwards indicating that the clinical effects of Minofit® and SNMC were similar.In conclusion,having a β-GZ content and clinical effects similar to those of SNMC,Minofit® should demonstrate a high degree of usefuness as a glycyrrhizin injection product.
- 日本医療薬学会の論文
日本医療薬学会 | 論文
- O17-003 視覚障害者に対する手技指導の標準化を目的とした視覚障害擬似体験インスリン注射院内実習(一般演題 口頭発表,糖尿病/後発医薬品,医療薬学の創る未来 科学と臨床の融合)
- 20H-16 Basal-Bolus療法におけるインスリンデテミルの有効性(使用状況調査・意識調査,来るべき時代への道を拓く)
- 30-P2-43 2種類のインスリン試薬を用いた化学発光酵素免疫測定法によってFactitious hypoglicemiaを証明しえた一例(副作用・有害事象,社会の期待に応える医療薬学を)
- 28-04-20 ペン型インスリン注射器の精度に及ぼす注入時抵抗とカートリッジ内気泡の影響
- P-610 ファブリー病に対する「ファブラザイム^[○!R]」投与時の「過敏反応発現時の対処方法」の一部改変により副作用防止に至った1症例(8.有害事象・副作用(基礎と臨床)1,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-)